俞哲 刘军权 李佳佳 王琛 王飞 李晓鸥 骆欣

[摘要] 目的 探讨多种自体免疫细胞与恩替卡韦联合治疗慢性乙型活动性肝炎的抗病毒疗效。 方法 将2015年4~9月我院收治的慢性活动性乙型病毒性肝炎患者26例分为两组(对照组和联合治疗组),两组均予以抗病毒治疗,其中联合治疗组12例接受多细胞免疫疗法联合恩替卡韦治疗,对照组14例单用恩替卡韦治疗。并分离单核细胞,体外培养γδ T细胞、NK细胞、NKT细胞,治疗8~12周后评价其疗效。 结果 治疗前两组患者在ALT、HBsAg、HBeAg、HBV DNA比较无统计学差异,联合治疗组HBsAg下降速率(治疗前/治疗后)与对照组比较有统计学差异(4.15±0.86 vs 1.80±0.15,t=2.09,P<0.05);ALT、HBV DNA在治疗前后,联合治疗组下降幅度大于对照组,但差异无统计学意义(P>0.05);而HBeAg两组对比无显著性差异。联合组不良反应轻微。 结论 自体多免疫细胞疗法联合恩替卡韦可促进HBsAg清除,对HBV的清除可能有帮助。
[关键词] 自体免疫细胞;NK细胞;NKT细胞; γδT细胞;恩替卡韦;慢性乙型病毒性肝炎
[中图分类号] R575.1 [文献标识码] A [文章编号] 1673-9701(2016)06-0022-04
Study on the short-term efficacy of autologous immune cell therapy combined with entecavir in the treatment of chronic hepatitis B
YU Zhe LIU Junquan LI Jiajia WANG Chen WANG Fei LI Xiaoou LUO Xin
Department of Liver Disease of the Hangzhou Xixi Hospital, Hangzhou Sixth People's Hospital, Hangzhou 310023,China
[Abstract] Objective To evaluate the efficacy of treatment for hepatitis B virus combined entecavir with a variety of autoimmune cells. Methods 26 hospital patients with chronic hepatitis B were divided into two groups(control group and combination treatment group) voluntarily during the period from April to September in 2015. All patients were in accordance with the indications for anti viral treatment. The combination treatment group included 12 patients received treatment combined entecavir with a variety of autoimmune cells and the control group involved 14 patiens accepted treatment of entecavir alone. Mononuclear cells were isolated, γδ T cells, NK cells, NKT cells were cultured in vitro. The efficacy of the two groups were evaluated after 8-12 weeks. Results There were no statistically significant differences in ALT, HBsAg, HBeAg, HBV DNA between the two groups before treatment. There were significant differences in the decrease rate of HBsAg(before/after treatment) between the two groups(4.15±0.86 vs 1.80±0.15,t=2.09,P<0.05); The efficacy of treatment group was greater than the control group in ALT, HBV DNA, but there was no statistically significant difference(P>0.05). There was no significant difference between the two groups in the inhibition of HBeAg. Adverse reactions in the treatment group were mild. Conclusion Multicellular autologous immunotherapy combined with entecavir could promote removal of HBsAg. Multicellular autologous immunotherapy may be helpful to the removal of HBV.
[Key words] Autologous immune cells; NK cell; NKT cell; γδT cell; Entecavir; Chronic hepatitis B
多免疫细胞疗法是一群具有较强免疫活性的细胞联合治疗相应疾病的简称,主要包括病毒特异性CTL、NK细胞、γδT细胞、NKT细胞等多种细胞。其中NK细胞与NKT细胞是肝脏固有免疫应答反应中的主要淋巴细胞,这两种细胞约占肝脏淋巴细胞的50%。当HBV急性感染时,肝脏内的NKT能直接激活细胞防御基因家族,诱导β干扰素的分泌,直接抑制病毒DNA复制[1-4]。γδT细胞介于固有和适应性免疫的T细胞,是免疫防御的第一防线,具有免疫调节、参与多种细菌与病毒的免疫应答等作用[5]。提高机体的T淋巴细胞和抗原提呈细胞的细胞免疫功能及增加协同细胞因子等多种方法联合对于清除病毒、打破免疫耐受将起到重要的作用[6]。……